Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

NCT00066352 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

Interventions

DRUG: bortezomib

Sponsor

University Health Network, Toronto

Collaborators

[object Object]